<DOC>
	<DOCNO>NCT01730482</DOCNO>
	<brief_summary>This study design describe metabolism AT1001 ( migalastat HCl ) contribution metabolism urinary excretion overall elimination part continue assessment safety effectiveness drug . This Phase 1 , single-site , open-label , single dose study absorption , metabolism excretion radiolabeled AT1001 healthy male subject 30 55 year age , inclusive . Six subject dose , goal least 4 subject complete study follow-up . All subject screen within 28 day admission Clinical Unit . Subjects confine clinical unit 10 day dose return clinic follow-up visit 28 day dose . Each subject receive single oral dose AT1001 aqueous solution contain 150 mg [ 14C ] AT1001 ( 1 Î¼Ci ) . Blood , duodenal bile , expire air , urine , feces sample collect specified time point dose throughout period confinement study site . Safety assess throughout study monitor clinical laboratory test , ECGs , physical examination , vital sign , adverse event . The total duration study subject approximately 8 week .</brief_summary>
	<brief_title>A Study Assess Absorption , Metabolism Excretion Migalastat Hydrochloride ( AT1001-014 )</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Healthy male subject age 30 55 year , inclusive Body mass index ( BMI ) &gt; =18.0 &lt; =30.0 weigh least 60 kg Anticipated , regular , average bowel movement 12 per day No clinically significant abnormal finding physical exam , vital sign , serum chemistry , hematology , urinalysis value , deem principal investigator Willing avoid take overthecounter medication 7 day prescription drug 14 day prior Day 1 Willing abstain sexual intercourse employ barrier method contraception inpatient clinic confinement followup visit Willing avoid ingestion broccoli , brussels sprout , grapefruit , grapefruit juice , charbroiled meat period confinement clinical unit Willingness consume fiberrich diet period confinement clinic Willingness avoid vigorous physical activity inpatient clinic confinement followup visit Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure , study restriction Provide write informed consent participate study Any previous ongoing clinically significant illness , medical condition , medical history , physical finding , ECG finding , laboratory abnormality , investigator 's opinion , could affect safety subject , alter absorption , distribution , metabolism , excretion study drug , could impair assessment study result History presence significant ophthalmic , cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic psychiatric disease History major surgical procedure within 30 day screen History blood plasma donation blood loss ( &gt; 400 mL ) within 60 day screen History drug alcohol abuse addiction within 2 year screen Intake 2 alcoholic drink per day within past 7 day use alcohol , grapefruit , caffeinecontaining food beverage within 72 hour prior Day 1 Selfreported smoker ( occasional frequent ) positive urine cotinine test ( measure screen baseline ) exceed local laboratory 's low limit detection . Presence history severe adverse reaction drug ; history hypersensitivity allergic reaction AT1001 related iminosugars Receipt investigational agent participation interventional clinical trial within past 30 day Participation clinical study involve administration [ 14C ] label compound ( ) within last 12 month . A subject 's previous effective dose review medical investigator ensure risk contamination/carryover current study At Day 1 , drug toxicology screen positive illicit substance , alcohol Anticipated need alcohol , tobacco , drug period confinement clinical unit</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>excretion</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>migalastat hydrochloride</keyword>
	<keyword>AT1001</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Fabry disease</keyword>
</DOC>